Study of Tofacitinib in Refractory Dermatomyositis (STIR): Proof of Concept, Open-Label Study of 10 Patients
Phase of Trial: Phase I
Latest Information Update: 21 Feb 2018
At a glance
- Drugs Tofacitinib (Primary)
- Indications Dermatomyositis
- Focus Proof of concept; Therapeutic Use
- Acronyms STIR
- 15 Feb 2018 Planned End Date changed from 1 Dec 2018 to 1 Jun 2019.
- 15 Feb 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Oct 2018.
- 25 Jan 2017 Status changed from not yet recruiting to recruiting.